BIOMARCADORES PARA DIAGNÓSTICO DE DEMENCIA

VolverVolver

Resultados 48 resultados LastUpdate Última actualización 23/03/2019 [17:04:00] pdf PDF

Solicitudes publicadas en los últimos 60 días / Applications published in the last 60 days

Página1 de 2 nextPage   por página


METHODS FOR MEASURING CONCENTRATIONS OF BIOMOLECULES IN BIOFLUIDS

NºPublicación: US2019086422A1 21/03/2019

Solicitante:

C2N DIAGOSTICS LLC [US]

WO_2018148593_PA

Resumen de: US2019086422A1

The present invention provides methods for measuring the absolute concentration of Tau, and other protein, peptide fragments and proteoforms in CSF and plasma samples collected from a subject. Such biomolecules may be implicated in one or more neurological and neurodegenerative diseases or disorders. Also provided is a method for determining whether a therapeutic agent affects the CSF or plasma concentration of a central nervous system derived biomolecule. Also provided are kits for performing the methods of the invention.

traducir

ALZHEIMER'S DISEASE EARLY DIAGNOSIS AND/OR PROGNOSIS IN CIRCULATING IMMUNE CELLS BASED ON HEPARAN SULFATES AND/OR OF HEPARAN SULFATE SULFOTRANSFERASES

NºPublicación: US2019086428A1 21/03/2019

Solicitante:

UNIV PARIS VAL DE MARNE [FR]
ASSIST PUBLIQUE HOPITAUX DE PARIS [FR]

WO_2017158045_PA

Resumen de: US2019086428A1

The present invention relates to a method of prognosis and/or diagnosis of Alzheimer's disease by determining the level and/or cellular distribution of heparan sulfates (HS) and/or heparan sulfate sulfotransferases (HSSTs) from isolating circulating immune cells in said circulating immune cells.

traducir

DIAGNOSTIC BIOMARKER PROFILES FOR THE DETECTION AND DIAGNOSIS OF ALZHEIMER'S DISEASE

NºPublicación: US2019086429A1 21/03/2019

Solicitante:

ROWAN UNIV [US]

US_2014315736_A1

Resumen de: US2019086429A1

The present invention provides methods, compositions and kits for the detection of Alzheimer's disease (AD) diagnostic biomarkers, for the diagnosis of AD, for the identification of a subject at risk for developing AD, and for the generation of patient-specific AD diagnostic biomarker profiles.

traducir

DIAGNOSTIC MARKER FOR DEMENTIA AND METHOD FOR IDENTIFYING CONTRACTION OF DEMENTIA USING SAID MARKER

NºPublicación: EP3457133A1 20/03/2019

Solicitante:

HASHIMOTO YASUHIRO [JP]
FUKUSHIMA MEDICAL UNIV [JP]

WO_2017195778_A1

Resumen de: EP3457133A1

An object of the present invention is to develop a biomarker for discriminating dementia, particularly, Alzheimer's disease and mild cognitive impairment which can progress to Alzheimer's disease, from other central nervous system diseases, or capable of determining a pathological condition of dementia, and provide a method for diagnosing dementia early and a method for determining a pathological condition of dementia, using the biomarker. A transferrin glycoprotein containing a glycan having at least one mannose at a non-reducing end or a transferrin fragment containing the glycan is used as a diagnostic marker for Alzheimer's disease.

traducir

METHODS FOR APOLIPOPROTEIN DETECTION

NºPublicación: EP3457140A1 20/03/2019

Solicitante:

BIOCROSS S L [ES]
INST DE SALUD CARLOS III [ES]
CENTRO DE INVESTIG BIOMEDICA EN RED DE ENFERMEDADES NEURODEGENERATIVAS CIBERNED [ES]

JP_2018533022_A

Resumen de: EP3457140A1

The present invention relates to methods for the detection and quantification of apolipoproteins and isoforms thereof in a sample, as well as to predictive methods of the probability of neurodegenerative or cardiovascular disease development based on apolipoprotein levels as determined by the detection methods of the invention.

traducir

Methods of treating or preventing amyloid related imaging abnormalities associated with alzheimer's disease treatment

NºPublicación: AU2017301736A1 14/03/2019

Solicitante:

BIOGEN CHESAPEAKE LLC

CA_3032289_A1

Resumen de: AU2017301736A1

A method of treating or preventing amyloid related imaging abnormalities (ARIA) in patients receiving one or more course of medical treatment for Alzheimer's Disease includes administrating a SUR1-TRPM4 channel inhibitor, such as glyburide, in an amount effective to prevent the formation or reduce the size of one or more ARIAs in the brain.

traducir

DEVICE AND METHOD FOR DIAGNOSIS OF ALZHEIMER'S SYMPTOMS

NºPublicación: WO2019049705A1 14/03/2019

Solicitante:

CONTROL OF INNATE IMMUNITY TECH RESEARCH ASSOCIATION [JP]
HAMAMATSU PHOTONICS KK [JP]
NATIONAL UNIV CORPORATION KAGAWA UNIV [JP]

Resumen de: WO2019049705A1

In order to provide a simple and highly accurate pathological index for Alzheimer's disease, this Alzheimer's disease diagnosis device is provided with: a measurement means for measuring, in peripheral blood, one or more selected from the group consisting of superoxide production activity, myeloperoxidase activity, oxidized LDL level, phagocytosis, triglyceride, fasting blood glucose, total cholesterol, hemoglobin A1c, and insulin; and a displaying means for displaying an index determined by the measurement means as a pathological index for Alzheimer's disease.

traducir

CAMELID SINGLE-DOMAIN ANTIBODY DIRECTED AGAINST PHOSPHORYLATED TAU PROTEINS AND METHODS FOR PRODUCING CONJUGATES THEREOF

NºPublicación: US2019077853A1 14/03/2019

Solicitante:

HOFFMANN LA ROCHE [CH]
PASTEUR INSTITUT [FR]
COMMISSARIAT ENERGIE ATOMIQUE [FR]
CENTRE NAT RECH SCIENT [FR]

JP_2017506068_A

Resumen de: US2019077853A1

The present invention relates to variable domains of a camelid heavy-chain antibodies directed against a phosphorylated tau protein and conjugates thereof. The present invention also relates to the use of these domains or conjugates for treating or diagnosing disorders mediated by neurofibrillary tangles, neuropil threads or dystrophic neurites, such as tauopathies.

traducir

SYNAPTIC PROTEIN BIOMARKERS AND DIFFERENTIAL DIAGNOSIS OF ALZHEIMER'S DISEASE AND OTHER NEURODEGENERATIVE DISORDERS

NºPublicación: EP3452828A1 13/03/2019

Solicitante:

NANOSOMIX INC [US]

WO_2017193115_A1

Resumen de: WO2017193115A1

The present invention relates to synaptic protein biomarkers and diagnostic and prognostic methods for Alzheimer's disease and other neurodegenerative disorders. The invention also provides compositions for detecting the synaptic protein biomarkers as well as compositions and methods useful for early diagnosis and/or treatment of Alzheimer's disease and other neurodegenerative disorders. The invention also provides methods for detecting biomarkers in vesicles (e.g., exosomes) isolated from a biological sample.

traducir

ASSAY FOR THE DIAGNOSIS OF A NEUROLOGICAL DISEASE

NºPublicación: EP3452830A1 13/03/2019

Solicitante:

EUROIMMUN MEDIZINISCHE LABORDIAGNOSTIKA AG [DE]
ADX NEUROSCIENCES NV [BE]

CN_109073661_A

Resumen de: EP3242134A1

The present invention relates to a diagnostically useful carrier comprising a means for capturing Neurogranin, a means for capturing BACE1 and preferably a means for capturing one or more additional biomarkers; a kit comprising the diagnostically useful carrier, optionally further comprising a means for detecting Neurogranin, a means for detecting BACE1 and preferably a means for detecting the one or more additional biomarkers; and a method comprising the steps contacting a sample from a subject with a means for capturing Neurogranin, isolating the means for capturing Neurogranin from the sample and contacting a sample from a subject with a means for capturing BACE1 and isolating the means for capturing BACE1 from the sample. The diagnosis aims to distinguish a neurodegenerative disease, preferably mild Alzheimer's disease, and depression with or without cognitive impairment.

traducir

ANTIBODIES RECOGNIZING TAU

NºPublicación: EP3452508A1 13/03/2019

Solicitante:

PROTHENA BIOSCIENCES LTD [IE]

KR_20190003647_A

Resumen de: WO2017191560A1

The invention provides antibodies that specifically bind tau. The antibodies inhibit or delay tau-associated pathologies and associated symptomatic deterioration.

traducir

METHOD FOR DIAGNOSING ALZHEIMER'S DISEASE USING SIGNAL PEPTIDE AS INDICATOR

NºPublicación: US2019071520A1 07/03/2019

Solicitante:

TOAGOSEI CO LTD [JP]
UNIV NAGOYA NAT UNIV CORP [JP]

JP_WO2017150680_A1

Resumen de: US2019071520A1

This method for aiding Alzheimer's detection provided by the present invention includes: determining a profile of signal peptides contained in a bodily fluid from a test subject, and comparing the signal peptide profile thus determined for the test subject with a previously-determined profile of signal peptides in a bodily fluid from a healthy subject. A difference between the signal peptide profile of the test subject and the signal peptide profile of the healthy subject at a specific molecular weight is then associated with the test subject's suffering from or developing Alzheimer's.

traducir

METHODS OF USING AN ACTIVATOR OF CEREBLON FOR NEURAL CELL EXPANSION AND THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS

NºPublicación: EP3450571A1 06/03/2019

Solicitante:

CELGENE CORP [US]

JP_2017511814_A

Resumen de: EP3450571A1

The invention provides an in vitro method for (a) inducing differentiation of CNS progenitor / precursor cells into CNS cells, (b) improving proliferation of CNS cells or CNS progenitor / precursor cells, or (c) improving survival of CNS cells or CNS progenitor / precursor cells, comprising contacting said cells with (i) a BRD7 antagonist, or (ii) an Ikaros antagonist. The invention further provides a composition comprising (i) a BRD7 antagonist, and/or (ii) an Ikaros antagonist, for use in a method of: (a) treating or preventing a central nervous system (CNS) cell disease, disorder or condition, or a symptom thereof, in a patient; (b) treating an injured CNS tissue in a patient; (c) engraftment of CNS cells, or CNS progenitor / precursor cells thereof, in a CNS tissue of a subject; (d) improving proliferation of CNS cells, or CNS progenitor / precursor cells thereof, in a CNS tissue of a subject; or (e) increasing CNS cell mass in a CNS tissue of a subject.

traducir

METHOD FOR IDENTIFYING INHIBITORS OF PRIMARY NUCLEATION OF AMYLOID-BETA AGGREGATION

NºPublicación: EP3449260A1 06/03/2019

Solicitante:

FORSCHUNGSZENTRUM JUELICH GMBH [DE]

CN_109073656_A

Resumen de: WO2017186203A1

The invention relates to a method for identifying inhibitors of the primary nucleation of amyloid-beta aggregation, comprising the following steps: a) A-beta species is provided in a buffer; b) the amyloid-beta aggregation is determined. The method is characterised in that c) two A-beta monomer units with a linker arranged between the A-beta monomers is selected as the A-beta species. Also disclosed are a linker used for that purpose, a kit and the uses thereof.

traducir

Method and System for the Diagnosis, Prevention or Treatment of Alzheimer s and Related Disease by Measuring, Inhibiting or Arresting Amyloid Plaque Development

NºPublicación: US2019062738A1 28/02/2019

Solicitante:

POSTREL RICHARD [US]

Resumen de: US2019062738A1

The present invention features systems and methods for preventing amyloid plaque development by treating plaque precursors to arrest or reverse binding of the plaque forming elements. Proteins, protein binding precursors, fragments, other bioactives or biosimilars are inserted to arrest plaque precipitation and aggregation. Hereditary cystatin C Amyloid Angiopathy (HCCAA) is a disease characterized by early and prolific plaque formation whose effective management is analogous to that of other more common amyloidosis. The cystatin C protein that serves as the key to HCCAA plaques colocalizes, coprecipitates and coglommerates with proteins found in other plaques such as those in Alzheimer's disease. The systems, including chemical and biochemical interventions, useful for treating HCCAA are applicable to slowing, preventing and even reversing these amyloids.

traducir

NEURONAL VIABILITY FACTOR AND USE THEREOF

NºPublicación: US2019064189A1 28/02/2019

Solicitante:

INSTITUT NATIONAL DE LA SANTE ET DE LA RECH MEDICALE [FR]
CENTRE NAT RECH SCIENT [FR]

ES_2623464_T3

Resumen de: US2019064189A1

The present invention concerns a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound selected in the group comprising (i) a polypeptide comprising an amino acid sequence selected in the group comprising the amino acid sequence of the long isoform in Homo sapiens of the RdCVF2 gene (SEQ ID NO: 10), orthologs, derivatives and fragments thereof, (ii) a polynucleotide coding for said polypeptide, (iii) a vector comprising said polynucleotide, and (iv) a host cell genetically engineered expressing said polypeptide; the use of such a composition for the manufacture of a medicament for treating and/or preventing a neurodegenerative disorder in a subject; and a method of testing a subject thought to have or be predisposed to having a neurodegenerative disorder.

traducir

Brain Derived PPARa Ligands

NºPublicación: US2019060269A1 28/02/2019

Solicitante:

UNIV RUSH MEDICAL CENTER [US]

JP_2018517728_A

Resumen de: US2019060269A1

Methods of modulating peroxisome proliferator-activated receptor α (PPARα) activity in a cell in a subject In need thereof are provided. The methods include administering an effective amount of a PPARα ligand to the subject where the PPARα ligand is selected from 3-hydroxy-2,2-dimethyl butyrate (HMB), hexadecananamide (HEX) and 9-octadecenamide (OCT), Methods of treating dementia, neurodegenerative disorders, lysosomal storage diseases and body weight disorders in a subject in need thereof are provided. The methods include administering an effective amount of a PPARα ligand to the subject.

traducir

GLYCOPEPTIDES AND USES THEREOF

NºPublicación: US2019060399A1 28/02/2019

Solicitante:

UNIV ARIZONA [US]

US_2016166639_A1

Resumen de: US2019060399A1

The present invention provides glycopeptides comprising a peptide that is covalently linked to a saccharide. The peptide portion of the glycopeptides of the invention has from about 20 to about 40 amino acid residues and at least 75% sequence identity to SEQ ID NO:1, 2, or 3. The saccharide moiety portion of the glycopeptides of the present invention comprises from 1 to about 8 carbohydrates. The present invention also relates to using the glycopeptides of the invention in treating various neurodegenerative diseases.

traducir

COMPOUND FOR SPECIFICALLY BINDING TO AMYLOID B-PROTEIN

NºPublicación: US2019062349A1 28/02/2019

Solicitante:

NEUBORON MEDTECH LTD [CN]

JP_2019503372_A

Resumen de: US2019062349A1

Provided is a compound for specifically binding to amyloid β-protein. The compound has thereon a nuclide with a large thermal neutron capture cross section and the compound is capable of specifically binding to the amyloid β-protein. The property of the compound allows it to be used in conjunction with a neutron capture therapy device to eliminate amyloid β-protein. Similarly, when the compound is labelled with radioactive element 11C, the compound can also be used in conjunction with PET/CT for determining the part of the brain where amyloid β-protein is deposited, for diagnosing Alzheimer's disease. Also disclosed is a preparation process for the compound. The beneficial effect of the present disclosure is to make the therapy and diagnosis of Alzheimer's disease more targeted by providing the compound for specifically binding to amyloid β-protein.

traducir

ANTIBODIES RECOGNIZING ALPHA-SYNUCLEIN

NºPublicación: US2019062415A1 28/02/2019

Solicitante:

PROTHENA BIOSCIENCES LTD [IE]

CN_109180812_A

Resumen de: US2019062415A1

The invention provides monoclonal antibody 5C1 and related antibodies. The 5C1 antibody binds to an epitope within residues 118-126 of α-synuclein. The antibodies of the invention are useful, for example, for treating and/or diagnosing disorders associated with α-synuclein, particularly accumulation of α-synuclein deposits. Such disorders include Lewy body diseases, such as Parkinson's disease, Diffuse Lewy Body Disease (DLBD), Lewy body variant of Alzheimer's disease (LBV), Combined Alzheimer's and Parkinson disease, pure autonomic failure and multiple system atrophy (MSA).

traducir

EPITOPES IN AMYLOID BETA MID-REGION AND CONFORMATIONALLY-SELECTIVE ANTIBODIES THERETO

NºPublicación: JP2019505166A 28/02/2019

Solicitante:

\u30B6\u30FB\u30E6\u30CB\u30D0\u30FC\u30B7\u30C6\u30A3\u30FB\u30AA\u30D6\u30FB\u30D6\u30EA\u30C6\u30A3\u30C3\u30B7\u30E5\u30FB\u30B3\u30ED\u30F3\u30D3\u30A2

US_2018319856_A1

Resumen de: WO2017079833A1

The disclosure pertains to conformational epitopes in A-beta, antibodies thereto and methods of making and using immunogens and antibodies specific thereto.

traducir

COMPOSITIONS AND METHODS FOR TREATING FRONTOTEMPORAL DEMENTIA

NºPublicación: SG11201900123TA 27/02/2019

Solicitante:

ANNEXON INC [US]

CA_3030872_A1

Resumen de: SG11201900123TA

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property 111111111111111111111111111 11111111111111111 01011101H1111111111111111111111 0111111 Organization 0 International Bureau (10) International Publication Number (43) International Publication Date .....0\"\"\" WO 2018/017711 Al 25 January 2018 (25.01.2018) WI P0 I P C T (51) International Patent Classification: A61K 39/395 (2006.01) GO1N 33/532 (2006.01) G01N 33/53 (2006.01) A61K 49/16 (2006.01) A61P 25/00 (2006.01) (21) International Application Number: PCT/US2017/042846 (22) International Filing Date: 19 July 2017 (19.07.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/364,013 19 July 2016 (19.07.2016) US (71) Applicant: ANNEXON, INC. [US/US]; 180 Kimball Way, 2nd Floor, Suite 200, South San Francisco, CA 94080 (US). (72) Inventors: SANKARANARAYANAN, Sethu; 4720 Fal- _ staff Avenue, Fremont, CA 94555 (US). YEDNOCK, Ted; 184 Arroyo Road, Forest Knolls, CA 94333 (US). — = Agent: HALSTEAD, David, P. et al.; Foley Hoag (74) LLP, Seaport West, 155 Seaport Boulevard, Boston, MA = 02210-2600 (US). Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, = (81) _ CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, K

traducir

PROTEIN-BASED THERAPY AND DIAGNOSIS OF TAU-MEDIATED PATHOLOGY IN ALZHEIMER'S DISEASE FIELD

NºPublicación: RU2018102103A 21/02/2019

Solicitante:

\u0410\u041A\u0421\u041E\u041D \u041D\u042C\u042E\u0420\u041E\u0421\u0410\u0419\u0415\u041D\u0421 \u0421\u0415

CN_109265543_A

Resumen de: EP3275461A1

The invention provides unique therapeutic and diagnostic antibodies, as well as their fragments, portions, derivatives, and variants thereof, that bind regions of the tau protein that contribute to the initiation and propagation of pathological tau-tau interactions, as well as methods of making them. The invention also relates to methods of using those antibodies for diagnostics, prevention, and treatment of Alzheimer's disease and related tauopathies. The present invention also provides a method for a prophylactic and therapeutic treatment of Alzheimer's disease and other neurodegenerative tauopathies. This method entails the injection of antibodies and/or peptide vaccines that elicits an immune response directed to pathological tau proteins and tau deposits in the brains of patients. Suitable vaccines represent a tau peptide carrying one or more of the tau therapeutic epitopes provided herein.

traducir

METHOD FOR MEASURING PHOSPHORYLATED TAU PROTEIN

NºPublicación: JP2019027952A 21/02/2019

Solicitante:

\u4EAC\u90FD\u5E9C\u516C\u7ACB\u5927\u5B66\u6CD5\u4EBA,
\u30B7\u30B9\u30E1\u30C3\u30AF\u30B9\u682A\u5F0F\u4F1A\u793E

US_2019033328_A1

Resumen de: US2019033328A1

Disclosed is a method for measuring phosphorylated tau protein in a biological sample collected from a subject, comprising the steps of: preparing a measurement sample containing a non-capture bead and a capture bead to which an immune complex is bound, by forming the immune complex of the phosphorylated tau protein in the biological sample, a capture antibody and a detection antibody on the capture bead, in the presence of the non-capture bead; and detecting a signal derived from the immune complex in the measurement sample.

traducir

APOE MODIFICATIONS AND USES THEREOF

Nº publicación: WO2019035006A1 21/02/2019

Solicitante:

UNIV GEORGETOWN [US]

Resumen de: WO2019035006A1

Provided herein are methods for detecting a cerebrospinal fluid-specific (CSF- specific) glycoform of Apolipoprotein E (APOE) in a subject.

traducir

Página1 de 2 nextPage por página

punteroimgVolver